KANGMEI康美品牌怎么样 申请店铺

外推网助力KANGMEI康美品牌出海！将品牌入驻外推网，定制KANGMEI康美品牌推广信息，可以显著提高KANGMEI康美产品曝光，简直是跨境电商爆单神器！目前仅需1000元/年哦~

康美药业股份有限公司（以下简称"康美药业"）成立于1997年，是一家以中药饮片、化学原料药及制剂生产为主导，集药品生产、研发及药品、医疗器械营销于一体的现代化大型医药企业、国家级重点高新技术企业。2001年3月康美药业A股股票在上海证券交易所挂牌上市，证券代码：600518；公司现有总股本169,437万股，总资产71亿元，净资产45亿多元。2009年康美药业实现营业收入23亿多元，实现利税6亿多元。康美药业先后通过了化学药GMP，中药GMP、GSP认证，以及ISO14001、ISO9001和GBT28001等管理体系认证。

康美药业拥有1个化学药品生产基地、2个中药饮片生产高技术产业化示范基地、1个中药饮片物流配送中心、1个省级企业技术中心、1个博士后科研工作站；总投资10多亿元的中药物流配送中心和具有中医特色的综合医院项目正在施工建设。目前康美药业产品系列包括4个国家级新药在内的20多种化学药品及原料药，各类中药饮片1,000多种，12,000多个品规。康美药业与中国中医研究院、广州中医药大学等国内中医药科研机构紧密合作，组建以中共中央委员、全国政协教科文卫体委员会副主任、中国宋庆龄基金会副主席张文康、中国科学院院士陈可冀、中国工程院院士王永炎、石学敏、刘耕陶等多位医药界权威和医药泰斗为顾问的公司专家队伍，形成强大的外围技术支撑团队，为企业生产和产品开发提供了强势的技术支持。康美药业"甲磺酸多沙唑嗪项目"、"中药饮片产业化示范项目"先后被列为国家高技术产业化技术工程专项、国家"十一五"规划项目。

未来，康美药业将立足医药，在进一步明确和增强中药饮片产业的核心竞争力，并确保将其做优、做强的同时，通过战略转型和战略投资，产业资源整合等形式，积极投资和发展医药诊疗、医药现代物流、原药材供应、药材成分提取和药食同源产品等中药上下游产业，使康美最终成为一个具有较强综合实力和竞争优势的医药资源型企业。

Kangmei Pharmaceutical Co., Ltd. (hereinafter referred to as "Kangmei pharmaceutical") was established in 1997. It is a modern large-scale pharmaceutical enterprise and national key high-tech enterprise with the production of Chinese herbal pieces, chemical raw materials and preparations as the leading role and the integration of drug production, research and development and drug and medical device marketing. In March 2001, Kangmei pharmaceutical A shares were listed on the Shanghai stock exchange with the securities code of 600518. The company has a total share capital of 1694.37 million shares, a total asset of 7.1 billion yuan and a net asset of more than 4.5 billion yuan. In 2009, Kangmei pharmaceutical industry realized more than 2.3 billion yuan of operating revenue and more than 600 million yuan of profits and taxes. Kangmei pharmaceutical industry has passed GMP, GMP and GSP certification for chemical drugs, and ISO14001, ISO9001 and gbt28001 management system certification. Kangmei Pharmaceutical Co., Ltd. has 1 chemical production base, 2 high-tech industrial demonstration bases for the production of Chinese herbal pieces, 1 logistics distribution center for Chinese herbal pieces, 1 provincial enterprise technology center, and 1 postdoctoral research workstation; the project of Chinese herbal medicine logistics distribution center with a total investment of more than 1 billion yuan and comprehensive hospital with Chinese medicine characteristics is under construction. At present, Kangmei pharmaceutical products include more than 20 kinds of chemicals and APIs including 4 national new drugs, more than 1000 kinds of Chinese herbal pieces, and more than 12000 product specifications. Kangmei Pharmaceutical Co., Ltd. cooperates closely with China Academy of traditional Chinese medicine, Guangzhou University of traditional Chinese medicine and other domestic scientific research institutions of traditional Chinese medicine. It has established many medical authorities and medicines, including Zhang Wenkang, member of the CPC Central Committee, deputy director of the education, culture, health and physical education Committee of the CPPCC National Committee, vice chairman of the Song Qingling foundation of China, Chen Keji, academician of the Chinese Academy of Sciences, Wang Yongyan, Shi Xuemin, Liu gentao, academician of the Chinese Academy of engineering Taidou is an expert team of the consultant company, forming a strong peripheral technical support team, and providing strong technical support for enterprise production and product development. Kangmei pharmaceutical "doxazosin mesylate project" and "Chinese Herbal Pieces industrialization demonstration project" have been listed as the national high-tech industrialization technology engineering project and the national "11th Five Year Plan" project. In the future, based on medicine, Kangmei pharmaceutical industry will further clarify and enhance the core competitiveness of Chinese herbal medicine Yinpian industry, and ensure to make it better and stronger. At the same time, through strategic transformation and investment, industrial resource integration and other forms, Kangmei pharmaceutical industry will actively invest in and develop the upstream and downstream production of Chinese medicine, such as medical diagnosis and treatment, modern logistics of medicine, supply of raw materials, extraction of ingredients of medicine and products of the same origin of medicine and food In the end, Kangmei will become a pharmaceutical resource-based enterprise with strong comprehensive strength and competitive advantage.

本文链接： https://brand.waitui.com/973f78086.html 联系电话：请联系客服添加 联系邮箱：请联系客服添加